Evelo Biosciences Announces Issuance of U.S. Patent Supporting Monoclonal Microbial Oncology Trials

CAMBRIDGE, Mass., Jan. 9, 2018 /PRNewswire/ -- Evelo Biosciences is developing monoclonal microbials, which are a new class of orally delivered, effective and safe medicines that act on the gut-immune axis to modulate immunity throughout the body to address a broad range of patient needs...